Recognition of the complex mechanisms of IBD pathogenesis and potential therapeutic interventions, including the effects of insulin, IGF-1, GLP-1 and TL1A on inflammation and intestinal microbiota, may contribute to the development of more effective therapeutic strategies for patients with inflammatory bowel diseases. This evidence concerns the gene GLP1R and inflammatory bowel disease.